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journal homepage: www.elsevier.com/locate/ihjDevelopment of a simple, yet dependable and robust diagnos-
tic marker in the diagnosis of acute coronary syndromes,
especially in an emergency setting, is not only important but is
also essential. Availability of such a test will ease the burden
on any emergency department to arrive at accurate diagnosis
to minimize possible errors of judgment. It is important that
such a test needs to be highly speciﬁc, sensitive, and easy to
perform. Though traditionally cardiac troponin T (cTnT) is
used as a biomarker to diagnose acute coronary syndromes, it
may not rise till 6 h after the onset of symptoms and may have
to be repeated within 8–12 h after the onset of pain in order to
conﬁrm or negate the diagnosis. Hence, more accurate and
dependable diagnostic test(s) that can detect coronary
disease earlier than 6 h after the onset of chest pain are
needed. Plasma levels of heart-type fatty acid-binding protein
(H-FABP) seem to ﬁll up such a gap. In the previous issue,
Vupputuri et al.1 outlined their experience with H-FABP in 54
patients presenting with acute ischemic chest pain and
concluded that it could be used as an early marker, while cTnT
could serve as a late marker for diagnosis of AMI before ECG
changes become apparent. In this context, it is prudent to
review brieﬂy the structure, function, and clinical signiﬁcance
of H-FABP.
1. H-FABP
H-FABP, also known as mammary-derived growth inhibitor, is
a protein that in humans is encoded by the FABP3 gene, which
is located on chromosome 1, with its speciﬁc location being
1p33-p32. H-FABP is a 51.2 kDa cytoplasmic protein that is
composed of 133 amino acids and is released from myocardial
cells following an ischemic episode.2 Like the nine other
distinct FABPs that have been identiﬁed, H-FABP is involved in
active fatty acid metabolism, where it transports fatty acids
from the cell membrane to mitochondria for oxidation. These
FABPs are believed to participate in the uptake, intracellular
metabolism, and/or transport of long-chain polyunsaturated
fatty acids (PUFAs). FABPs have modulatory inﬂuence on cell
growth and proliferation, and arrest growth of mammaryepithelial cells. Immunoreactivity of H-FABP was detected in
both ventricles and atria, in many striated muscles, parietal
cells of the stomach, renal epithelial cells, acinar and ductal
cells of the breast, ductal cells of the salivary gland, corpus
luteum, Leydig cells of the testis, adipocytes, vascular
endothelial cells, and terminally differentiated epithelia of
the respiratory, intestinal, and urogenital tracts.3,4 H-FABP was
not detected in old infarcts of the heart and necrotic
cardiomyocytes. Even morphologically normal cardiomyo-
cytes did not show H-FABP 1 h after acute ischemic lesions3
suggesting that these cardiomyocytes that appear to be
apparently normal are in fact non-viable cells. In this context,
it is noteworthy that exposure of primary cultures of rat
neonatal myocytes to saturated fatty acids (C16:0 and C18:0)
but not monounsaturated (C16:1 or C18:1) and polyunsaturat-
ed (C18:2, C18:3 and C20:4) resulted in cell death.5,6 Further-
more, PUFAs enhanced the expression of FABPs, and the
detrimental effect of saturated fatty acids was nulliﬁed by
unsaturated fatty acids5 indicating that one of the functions of
H-FABP could be to transport PUFAs to myocardial cells and
thus preserve their integrity. This is supported by the
observation that mice lacking H-FABP showed severe defect
in utilization of PUFAs and heart failed to efﬁciently take up
plasma PUFAs and use it as the main fuel. H-FABP deﬁciency
also led to acute exercise intolerance and localized cardiac
hypertrophy.7 These data are in agreement with the fact that
H-FABP is needed for cardiac intracellular lipid transport and
fuel selection and thus, plays a major role in metabolic
homeostasis.6 Thus, it is likely that release of H-FABP due to
ischemia may further aggravate cardiomyocyte function and
survival due to reduced or absent H-FABP that leads to
inefﬁcient transport PUFAs for use as fuel. In addition, those
who have consumed increased amounts of saturated fatty
acids and trans-fatty acids are more likely to be at increased
risk of further aggravation of myocardial damage since
saturated fatty acids and trans-fatty acids are toxic to
myocardial cells.5 This may explain the beneﬁt of consuming
PUFAs since they have been shown to nullify the toxic actions
of saturated fatty acids on myocardial cells.
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disease
In view of the importance of H-FABP in myocardial function, it
is quite but natural that its measurement in the plasma
formed a reliable test for myocardial ischemia. A sandwich
enzyme-linked immunosorbent assay (ELISA) developed back
in 1995 for H-FABP showed that the assay range was 0–250 ng/
ml, the minimum detection limit of the assay was 1.25 ng/ml,
and the plasma and urine H-FABP values were 3.65  1.81 ng/
ml and 3.20  2.70 ng/ml, respectively in normal healthy
subjects.8 This ELISA test8 mentioned above is more sensitive
than the one used by Vupputuri et al.1 Several studies
performed since have clearly established that H-FABP is a
reliable and early cardiac marker for diagnosis of acute
myocardial infarction (AMI) soon after the onset of symp-
toms.9 As a result of this reliability, several types of test
systems were also developed to measure both plasma and
urine H-FABP. In fact, there is now an attempt to use H-FABP
measurement as a biomarker to detect or exclude an early-
stage acute myocardial infarction (AMI), and results showed
that combining H-FABP and cardiac troponin T (cTnT) provides
the best performance for early AMI diagnosis.10 Hence, it is
time that measurement of H-FABP is done in all patients with
chest pain coming to the emergency to exclude or conﬁrm the
diagnosis of acute coronary syndromes. Perhaps, development
of a simpler method of detecting and measuring H-FABP may
encourage even smaller hospitals (especially in India, where
ELISA or other tests systems may not be available in rural
hospitals) to use this test for the beneﬁt of the patient. It is
possible to develop a simple strip test for H-FABP (similar to
glucose testing) that will encourage almost all hospitals to use
it in their emergency department. But the usefulness of H-
FABP in patients suspected of acute coronary syndrome is not
without controversy. Based on the results of a prospective
monocentre diagnostic accuracy study of H-FABP bedside
point of care (CardioDetect®) and ELISA tests in acute coronary
syndrome suspected patients presenting within 24 h of
symptom onset to the emergency department, it was
concluded that H-FABP testing improves diagnostic accuracy
in addition to clinical ﬁndings and electrocardiography, but it
is of no additional diagnostic value when hs-cTnT measure-
ments are also available.11 These results imply that additional
studies are needed to conﬁrm the usefulness of H-FABP in the
emergency department. Hence, it is recommended that a
larger number of patients (perhaps in thousands) and under
different settings such as urban and semi-urban hospitals
(small to midsize to large corporate and teaching hospitals)
need to be studied to assess the utility of H-FABP.
3. H-FABP in other conditions
In addition to its use in diagnosing acute coronary syndromes,
it is being realized that H-FABP may be useful to detect
myocardial functional status in other conditions including
congestive cardiac failure, sepsis, pulmonary thromboembo-
lism,12–14 etc. It is noteworthy that serum H-FABP concentra-
tions are increased in non-alcoholic fatty liver disease(NAFLD) and metabolic syndrome,15,16 suggesting that it (H-
FABP) may serve as a marker of insulin resistance that is
present and the existence of subclinical myocardial damage
in these patients. This association of H-FABP with inﬂamma-
tory conditions such as heart failure, coronary heart disease,
sepsis, metabolic syndrome, NAFLD, and insulin resistance17
is in close proximity to the similar association seen between
these conditions and A-FABP (adipose-FABP).18 It is interest-
ing that both H-FABP and A-FABP are expressed in subcuta-
neous and intramuscular adipocytes19 and the transcript of
H-FABP in brown adipose tissue (BAT) was increased about
100-fold by cold exposure, whereas that in white adipose
tissue (WAT) was negligible, and on treatment with norepi-
nephrine (NE), transcript level of H-FABP was elevated
markedly but that of A-FABP was not changed in brown
adipocytes.20 These results emphasize the involvement of H-
FABP in the regulatory role of autonomic nervous system on
adipose and cardiac tissues. Since catecholamines are pro-
inﬂammatory in nature,21 whereas acetylcholine, the princi-
pal neurotransmitter of parasympathetic nervous system, is
anti-inﬂammatory in nature,22 it is obvious that there is a
close positive and negative feed-back regulation among
catecholamines, acetylcholine, FABPs, inﬂammation, and
inﬂammatory conditions. These interactions indicate that
in acute coronary syndromes, it may be worthwhile to assess
the plasma levels of A-FABP (in addition to H-FABP),
cytokines, catecholamines, and adipokines to obtain a
comprehensive picture of the underlying molecular mecha-
nisms of the disease and their relationship to its progress and
prognosis. Clinicians are uniquely suited to adopt such an
approach to decipher and integrate the clinical picture with
the underlying pathophysiology. I trust that clinicians such as
Vupputuri et al.1 would take such a route in their future
endeavors.
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